EP. 1: Introduction and Exploring the Financial Burden of Follicular Lymphoma
Watch
EP. 2: Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma
EP. 3: Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy
Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and reduce chemotherapy toxicity.
EP. 4: Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma
Explore the advancements in bispecific antibodies for follicular lymphoma, addressing treatment options, toxicities, and unmet patient needs in cancer care.
EP. 5: Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma
Explore the latest insights on second-line therapies for follicular lymphoma, including the benefits and challenges of R2 treatment.
EP. 6: Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma
Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes.
EP. 7: Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma
EP. 8: Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
EP. 9: Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma
Explore the operational challenges and solutions in administering bispecific therapies for follicular lymphoma, focusing on patient safety and education.
EP. 10: Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma
Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities.
EP. 11: Optimizing Epcoritamab Dosing and Treatment Considerations in Second-Line Follicular Lymphoma
